References
- Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho ER. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy. Australia: Exon Publications, 2017. p. 3-22.
- Arnold M, De Vries E, Whiteman DC, Jemal A, Bray F, Parkin DM, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018;143(6):1305-14. https://doi.org/10.1002/ijc.31527 PMid:29659012
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338
- Fedorenko Z, Soumkina O, Gorokh Y, Goulak L, Koutsenko L. Cancer in Ukraine 2020-2021. Incidence, mortality, prevalence and other relevant statistics. In: Bulletin of the National Cancer Registry of Ukraine. Ukraine: National Cancer Registry of Ukraine; 2022. p. 86.
- Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-update. Eur J Cancer. 2022;170:256-84. https://doi.org/10.1016/j.ejca.2022.04.018 PMid:35623961
- Michielin O, Van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: Under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449-61. https://doi.org/10.1016/j.annonc.2020.07.005 PMid:32763452
- Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: Under the auspices of the ESMO guidelines committee. Ann Oncol. 2020;31(11):1435-48. https://doi.org/10.1016/j.annonc.2020.07.004 PMid:32763453
- Sekulovic LK, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, et al. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer. 2017;75:313-22. https://doi.org/10.1016/j.ejca.2017.01.012 PMid:28264791
- Carlino M, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002-14. https://doi.org/10.1016/S0140-6736(21)01206-X PMid:34509219
- Hoffmann M, Hayoz S, Özdemir BC. Prescription patterns, recurrence, and toxicity rates of adjuvant treatment for stage III/IV melanoma-a real world single-center analysis. Biology (Basel). 2022;11(3):422. https://doi.org/10.3390/biology11030422 PMid:35336796
- De Meza M, Ismail RK, Rauwerdink D, Van Not OJ, Van Breeschoten J, Blokx WA. Adjuvant treatment for melanoma in clinical practice-trial versus reality. Eur J Cancer. 2021;158:34-245. https://doi.org/10.1016/j.ejca.2021.08.044 PMid:34600790
- Hu HP. Clinical predictors of survival in real-world practice in stage IV melanoma. Cancer Rep (Hoboken). 2023;6(2):e1691. https://doi.org/10.1002/cnr2.1691 PMid:36161287